Graf D, Helmich-Kapp B, Graf S, Veit F, Lehmann N, Mann K
Endokrinologisch-nuklearmedizinische Praxisgemeinschaft Lüneburg.
Dtsch Med Wochenschr. 2012 Oct;137(41):2089-92. doi: 10.1055/s-0032-1305324. Epub 2012 Oct 2.
The American (ATA) and the European Thyroid Association (ETA) recommend a thyroid scintiscan for the detection of a suspected autonomy only when serum thyrotropin (TSH) levels are low or suppressed. If ultrasound reveals a thyroid nodule > 1.0 cm and TSH is normal, a fine-needle biopsy is recommended without a preceding scintiscan as the next step. The aim of this prospective study was to evaluate the incidence of reduced or suppressed TSH in 100 autonomous adenoma > 1.0 cm and to clarify, if normal TSH does substantially exclude a focal autonomy. When the study was conducted no data of German patients were available.
An unselected group of 496 patients with a nodular goiter was continuously screened by scintiscan in order to detect 100 autonomous adenoma > 1.0 cm for the study. The following investigations were carried out: ultrasound, scintiscan and laboratory tests (fT3, fT4, TSH, TPO-antibodies). The reference range of TSH was 0.4 to 4.0 µU/ml.
21% of patients (100/476) with a nodular goiter had a focal autonomy. 32 % (32/100) of autonomous adenoma revealed a reduced (< 0.4 µU/ml) or completely suppressed TSH, while in 68 % (68/100) normal TSH level were found.
In Germany autonomous adenoma are still frequent (21 % of all thyroid nodules). Most of them (68 %) reveal normal TSH levels. Our data demonstrate, that there is no relevant connection between TSH level and autonomous adenoma detected by scintiscan. In most cases, TSH is not able to discriminate, whether a nodule is autonomous or not. Biopsy of undetected autonomous nodules should not be performed, as they often show cytological features of follicular neoplasias. In thyroid nodules > 1.0 cm a scintiscan should routinely be performed in primary diagnostics to avoid unnecessary fine-needle biopsy of autonomous adenoma.
美国甲状腺协会(ATA)和欧洲甲状腺协会(ETA)建议,仅当血清促甲状腺激素(TSH)水平降低或被抑制时,才进行甲状腺闪烁扫描以检测疑似自主性病变。如果超声显示甲状腺结节>1.0 cm且TSH正常,建议在不进行闪烁扫描的情况下直接进行细针穿刺活检作为下一步检查。这项前瞻性研究的目的是评估100例直径>1.0 cm的自主性腺瘤患者中TSH降低或被抑制的发生率,并明确正常TSH水平是否能实质性排除局灶性自主性病变。在开展该研究时,尚无德国患者的数据。
对496例结节性甲状腺肿患者进行无选择的连续闪烁扫描筛查,以确定100例直径>1.0 cm的自主性腺瘤用于研究。进行了以下检查:超声、闪烁扫描和实验室检查(游离T3、游离T4、TSH、甲状腺过氧化物酶抗体)。TSH的参考范围为0.4至4.0 μU/ml。
21%(100/476)的结节性甲状腺肿患者存在局灶性自主性病变。32%(32/100)的自主性腺瘤TSH降低(<0.4 μU/ml)或完全被抑制,而68%(68/100)的患者TSH水平正常。
在德国,自主性腺瘤仍然很常见(占所有甲状腺结节的21%)。其中大多数(68%)TSH水平正常。我们的数据表明,TSH水平与闪烁扫描检测到的自主性腺瘤之间没有相关性。在大多数情况下,TSH无法区分结节是否具有自主性。未检测到的自主性结节不应进行活检,因为它们通常表现为滤泡性肿瘤的细胞学特征。对于直径>1.0 cm的甲状腺结节,在初步诊断时应常规进行闪烁扫描,以避免对自主性腺瘤进行不必要的细针穿刺活检。